The emergence of off-patent drugs is poised to reshape the treatment of type 2 diabetes. Previously restricted to premium formulations, this powerful GLP-1 treatment is now accessible to a broader patient population, potentially enhancing outcomes and reducing the expense for many who manage with the disease. This transition signifies a significant